Price · as of 2025
$48.28
Market cap 2.5B
Valuation
| Metric | Value | Upside |
|---|---|---|
| IC Value | $24.70 | -49% |
| P/E | -94.84 | |
| P/B | 11.56 | |
| P/S | 6.61 | |
| EV/EBITDA | 7923.68 | |
| PEG | -198.30 | |
| P/TBV | 12.20 |
Valuation history
Annual price overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | IC | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $2.90 | $255.49 | |||
| 2012 | $3.99 | $14.80 | |||
| 2013 | $3.65 | $12.99 | |||
| 2014 | $3.25 | $15.19 | |||
| 2015 | $5.14 | $16.55 | |||
| 2016 | $10.05 | $18.07 | |||
| 2017 | $35.35 | $23.53 | |||
| 2018 | $19.18 | $16.27 | |||
| 2019 | $11.95 | $15.46 | |||
| 2020 | $20.51 | $19.75 | |||
| 2021 | $8.32 | $12.87 | |||
| 2022 | $7.58 | $12.75 | |||
| 2023 | $8.75 | $18.23 | |||
| 2024 | $17.73 | $38.57 | |||
| 2025 | $32.34 | $25.31 |
Historic valuation ratios
Pick a category, then toggle metrics to compare.
Line items
Line items
Line items
About AxoGen, Inc.
AxoGen, Inc., along with its subsidiaries, specializes in creating and distributing medical devices for the surgical repair of injured or severed peripheral nerves. Their comprehensive product portfolio offers several innovative solutions. The Avance Nerve Graft is a ready-to-use, biologically active human nerve allograft designed to bridge gaps in severed nerves. This avoids the need for a second surgical site for tissue donation, thereby eliminating associated complications. For facilitating the gentle reconnection of severed peripheral nerves, the company offers the AxoGuard Nerve Connector, an extracellular matrix (ECM) derived from porcine submucosa. This same porcine submucosa ECM forms the basis of the AxoGuard Nerve Protector, which is utilized to encase and safeguard damaged peripheral nerves, supporting their reconstruction and preventing unwanted adhesions from surrounding soft tissues. Another ECM product, the AxoGuard Nerve Cap, isolates the nerve end from its environment to help mitigate the formation of painful neuromas. Furthermore, AxoGen provides the Avive Soft Tissue Membrane, a processed human umbilical cord membrane that functions as an absorbable covering for soft tissues, used to separate tissues within the surgical area. An additional tool available is the AxoTouch two-point discriminator, used for evaluating the density of nerve innervation on the skin's surface. These products are supplied to hospitals, surgery centers, and military medical facilities, catering to plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen's market reach extends across the United States, Canada, Germany, the United Kingdom, other European nations, South Korea, and internationally. The company's main operations are situated in Alachua, Florida.
- CEO
- Michael D. Dale
- Employees
- 622
- Beta
- 1.09
Scroll horizontally for additional metrics. Ticker column stays fixed.
| Basic Info | IC Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | Value | Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| AXGN | AxoGen, Inc. | $48.28 | 2.5B | $25.31 | -48% | -94.84 | 11.56 | 6.61 | 7923.68 | -198.30 | 12.20 | 74.31% | -3.49% | -6.97% | -13.49% | -5.23% | -7.38% | 0.52 | -1.02 | 5.11 | 2.62 | 167.09 | 47.83% | 20.21% | -26763.64% | -0.20% | 0.03 | -1.96% | 0.00% | 0.00% | 0.61% | -193.83 | -518.70 | 6.76 | 9.11 |
| AHCO | AdaptHealth Corp. | $6.50 | 883.67M | $24.88 | +283% | -21.68 | 0.94 | 0.44 | 6.41 | — | -1.29 | 17.52% | 5.74% | -2.18% | -4.27% | 5.39% | -1.50% | 1.25 | 1.76 | 1.02 | 0.67 | 3.57 | -185.25% | -0.49% | -6.96% | 15.32% | 0.84 | 6.35% | 0.00% | 0.00% | 15.64% | 17.33 | 14.72 | 0.99 | 1.00 |
| CTEV | Claritev Corporation | $26.13 | 445.46M | $84.75 | +224% | -0.98 | -1.60 | 0.29 | 10.29 | — | -0.06 | 27.61% | 4.67% | -29.45% | 632.60% | 0.76% | -5.66% | -26.64 | 0.11 | 0.86 | 0.59 | 9.71 | -83.03% | 3.74% | 16.85% | -4.42% | 0.45 | -0.27% | 0.00% | 0.00% | 0.00% | 108.60 | -398.56 | 5.07 | -0.44 |
| IART | Integra LifeSciences Hold… | $17.68 | 1.38B | $42.09 | +138% | -1.37 | 0.68 | 0.43 | -7.60 | -0.02 | -1.00 | 51.69% | 4.18% | -31.58% | -39.90% | 2.06% | -13.52% | 1.95 | 0.79 | 2.54 | 1.19 | -5.51 | 7361.20% | 1.53% | -281.28% | -6.38% | 0.11 | -1.49% | 0.00% | 0.00% | 0.03% | 36.28 | -54.77 | 1.52 | 1.08 |
| INMD | InMode Ltd. | $15.21 | 874.28M | $44.70 | +194% | 9.33 | 1.28 | 2.36 | 3.00 | — | 1.28 | 78.54% | 23.05% | 25.33% | 13.53% | 56.67% | 12.09% | 0.02 | — | 9.88 | 8.55 | -2.61 | -36.44% | -6.16% | -36.15% | 9.63% | 1.21 | 65.78% | 0.00% | 0.00% | 30.77% | 3.90 | 3.95 | 0.90 | 9.91 |
| IRMD | IRadimed Corporation | $91.86 | 1.17B | $46.05 | -50% | 56.29 | 13.37 | 15.10 | 39.50 | 337.72 | 13.87 | 76.75% | 31.20% | 26.82% | 24.78% | 53.01% | 21.71% | 0.00 | — | 7.98 | 6.37 | -1.66 | 16.67% | 14.43% | -2.48% | 1.36% | 2.45 | 43.94% | 1.19% | 66.90% | 1.19% | 46.44 | 70.67 | 14.49 | 56.80 |
| LFMD | LifeMD, Inc. | $3.68 | 177.97M | $19.57 | +432% | 11.50 | 7.76 | 0.93 | -98.32 | — | 7.85 | 79.75% | -3.95% | -3.66% | 176.78% | 67.59% | 21.87% | 0.27 | -5.64 | 1.25 | 1.11 | 20.08 | -56.60% | -8.66% | -120.72% | -0.69% | 0.20 | 10.91% | 1.73% | 19.90% | 13.18% | -19.45 | -120.44 | 0.77 | 0.31 |
| OPK | OPKO Health, Inc. | $1.35 | 1.01B | $12.81 | +849% | -3.96 | 0.70 | 1.47 | -23.20 | -1.36 | 3.34 | 21.10% | -36.08% | -37.19% | -17.14% | -14.78% | -10.92% | 0.34 | -2.02 | 3.97 | 3.38 | -1.56 | 291.13% | -14.90% | -8.48% | -21.35% | -1.22 | -13.78% | 0.00% | 0.00% | 6.16% | -4.38 | -5.02 | 1.58 | -0.64 |
| SANA | Sana Biotechnology, Inc. | $3.51 | 976.8M | — | — | -3.48 | 5.29 | — | -3.42 | — | -21.85 | 0.00% | 0.00% | 0.00% | -118.70% | -130.09% | -53.20% | 0.49 | — | 1.89 | 1.76 | -0.03 | -17.24% | — | -43.58% | -17.01% | -1.83 | -98.63% | 0.00% | 0.00% | 0.00% | -4.14 | -5.47 | — | -5.53 |
| TNDM | Tandem Diabetes Care, Inc… | $19.59 | 1.34B | $22.70 | +16% | -7.10 | 9.36 | 1.43 | -9.18 | -6.64 | 9.36 | 52.31% | -7.70% | -20.17% | -97.88% | -25.81% | -22.15% | 2.86 | -9.88 | 2.55 | 1.89 | -2.03 | 106.80% | 7.93% | -694.09% | -2.04% | -0.04 | -9.80% | 0.00% | 0.00% | 3.48% | -20.54 | -54.08 | 1.58 | 0.58 |
| TSHA | Taysha Gene Therapies, In… | $6.46 | 2.07B | $14.19 | +120% | -13.17 | 5.81 | 146.88 | -10.52 | — | 5.81 | 100.00% | -1130.65% | -1115.27% | -68.45% | 374.65% | -43.28% | 0.07 | -1753.94 | 12.23 | 12.04 | 2.80 | -5.56% | 17.28% | 14.99% | -6.54% | -3.51 | 318.13% | 0.00% | 0.00% | 15.73% | -10.26 | -12.09 | 116.02 | 6.04 |
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($24.70 ÷ $48.28) − 1 = -48.84% (IC, example).